Is it Now Time For Investors to Consider Selling Concert Pharmaceuticals (NASDAQ:CNCE) Stock? Concert Pharmaceuticals (NASDAQ:CNCE) Receives a DowngradeMizuho has cut Concert Pharmaceuticals (NASDAQ:CNCE) shares to a “Neutral” in a note revealed this morning, while they’ve also set an estimated 12-month price target at $23. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Ratings CoverageAmong 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by H.C. Wainwright on Monday, September 18. More important recent Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) news were published by: Businesswire.com which released: “Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief …” on December 18, 2017, also Seekingalpha.com published article titled: “Concert Pharmaceuticals: Materialized Income With Reasonable Valuation”, Blogs.Wsj.com published: “CFO Moves: Allergan PLC, Atlassian Corp., SAS AB, Concert Pharmaceuticals Inc.” on December 19, 2017.

Source: Wall Street Journal January 13, 2018 14:26 UTC